BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 30066611)

  • 1. Neurofilaments and 10-year follow-up in multiple sclerosis.
    Bhan A; Jacobsen C; Myhr KM; Dalen I; Lode K; Farbu E
    Mult Scler; 2018 Sep; 24(10):1301-1307. PubMed ID: 30066611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
    Rosenstein I; Axelsson M; Novakova L; Blennow K; Zetterberg H; Lycke J
    Mult Scler; 2022 May; 28(6):872-884. PubMed ID: 34392718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    van der Vuurst de Vries RM; Wong YYM; Mescheriakova JY; van Pelt ED; Runia TF; Jafari N; Siepman TA; Melief MJ; Wierenga-Wolf AF; van Luijn MM; Samijn JP; Neuteboom RF; Hintzen RQ
    Mult Scler; 2019 Jun; 25(7):958-967. PubMed ID: 29774770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
    Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
    Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
    Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
    Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
    Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
    Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients.
    Ferraro D; Guicciardi C; De Biasi S; Pinti M; Bedin R; Camera V; Vitetta F; Nasi M; Meletti S; Sola P
    Acta Neurol Scand; 2020 Jan; 141(1):16-21. PubMed ID: 31350854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
    Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
    Front Neurol; 2019; 10():1008. PubMed ID: 31608004
    [No Abstract]   [Full Text] [Related]  

  • 19. Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis.
    Gaetani L; Eusebi P; Mancini A; Gentili L; Borrelli A; Parnetti L; Calabresi P; Sarchielli P; Blennow K; Zetterberg H; Di Filippo M
    Mult Scler Relat Disord; 2019 Oct; 35():228-232. PubMed ID: 31404762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
    Peng L; Bi C; Xia D; Mao L; Qian H
    Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.